Results from a substudy of the ODYSSEY trial show that children being treated for tuberculosis (TB) and HIV at the same time can safely have the anti-HIV medicine dolutegravir twice a day. These results were published yesterday in The Lancet HIV journal. Around 50,000...
A once-a-day antiretroviral medicine that is low-cost and easy for children to take is also more effective at suppressing HIV than standard treatments, according to a global trial led by researchers at UCL.
It was announced at the 8th European AIDS Conference that the laureates of the Hector Research Award in HIV 2021 in clinical and/or epidemiological science was received Angela Colbers and David Burger on behalf of the ODYSSEY trial team! The winning paper Simplified...
July 2021
The World Health Organization (WHO), welcomes new findings presented at the International Pediatric HIV Workshop yesterday, on the superiority of dolutegravir (DTG) -based regimens in young children.
March 2021
Contributions made by the ODYSSEY trial have not gone unnoticed and as a result, has earned researchers the Radboud Institute for Health Sciences Societal Impact Award.
March 2021
The anti-HIV drug Dolutegravir improves outcomes for children with HIV infection when given in a 3-drug anti-HIV combination. These results come from the ODYSSEY trial which was presented at the Conference
UNIVERSAL, the newly funded European-African clinical research partnership will develop, evaluate and register two new antiretroviral formulations for infants and children newly diagnosed with HIV initiating antiretroviral therapy, and for children failing...
January, 2021
On 12 January 2021, the European Medicine Agency approved the use of dolutegravir 5mg dispersible tablets for treating HIV in young children living in Europe.
December, 2020
With the world engulfed by the COVID-19 pandemic, you may not have heard about some of the breakthroughs
November 2020